CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
CASI Pharma (CASI) Misses Q1 EPS by 5c, Revenues Beat
May 13, 2021 7:10 AM EDTCASI Pharma (NASDAQ: CASI) reported Q1 EPS of ($0.11), $0.05 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $5.74 million versus the consensus estimate of $5.05 million.
Wei-Wu He, Ph.D., CASI's Chairman, and Chief Executive Officer, commented, "We are pleased to report $5.7 million EVOMELA® revenues for the quarter. For the full year 2021, we... More
